Integrating quality into the cycle of therapeutic development

被引:114
作者
Califf, RM
Peterson, ED
Gibbons, RJ
Garson, A
Brindis, RG
Beller, GA
Smith, SC
机构
[1] Duke Clin Res Inst, Durham, NC 27710 USA
[2] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Kaiser Permanente San Francisco Med Ctr, San Francisco, CA USA
[5] Univ Virginia Hlth Syst, Charlottesville, VA USA
[6] Univ N Carolina, Chapel Hill, NC 27599 USA
关键词
D O I
10.1016/S0735-1097(02)02537-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The quality of healthcare, particularly as reflected in current practice versus the available evidence, has become a major focus of national health policy discussions. Key components needed to provide quality care include: 1) development of quality indicators and performance measures from specific practice guidelines, 2) better ways to disseminate such guidelines and measures, and 3) development of support tools to promote standardized practice. Although rational decision-making and development of practice guidelines have relied upon results of randomized trials and outcomes studies, not all questions can be answered by randomized trials, and many treatment decisions necessarily reflect physiology, intuition, and experience when treating individuals. Debate about the role of "evidence-based medicine" also has raised questions about the value of applying trial results in practice, and some skepticism has arisen about whether advocated measures of clinical effectiveness, the basic definition of quality, truly reflect a worthwhile approach to improving medical practice. We provide a perspective on this issue by describing a model that integrates quantitative measurements of quality and performance into the development cycle of existing and future therapeutics. Such a model would serve as a basic approach to cardiovascular medicine that is necessary, but not sufficient, to those wishing to provide the best care for their patients. (C) 2002 by the American College of Cardiology Foundation.
引用
收藏
页码:1895 / 1901
页数:7
相关论文
共 34 条
  • [1] [Anonymous], 2000, TO ERR IS HUMAN BUIL
  • [2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [3] Management of acute coronary syndromes:: acute coronary syndromes without persistent ST segment elevation -: Recommendations of the Task Force of the European Society of Cardiology
    Bertrand, ME
    Simoons, ML
    Fox, KAA
    Wallentin, LC
    Hamm, CW
    McFadden, E
    De Feyter, PJ
    Specchia, G
    Ruzyllo, W
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (17) : 1406 - 1432
  • [4] BRAUNWALD E, ACC AHA GUIDELINE UP
  • [5] A randomized study of the prevention of sudden death in patients with coronary artery disease
    Buxton, AE
    Lee, KL
    Fisher, JD
    Josephson, ME
    Prystowsky, EN
    Hafley, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) : 1882 - 1890
  • [6] Principles from clinical trials relevant to clinical practice: Part II
    Califf, RM
    DeMets, DL
    [J]. CIRCULATION, 2002, 106 (09) : 1172 - 1175
  • [7] Principles from clinical trials relevant to clinical practice: Part I
    Califf, RM
    DeMets, DL
    [J]. CIRCULATION, 2002, 106 (08) : 1015 - 1021
  • [8] Relationships between authors of clinical practice guidelines and the pharmaceutical industry
    Choudhry, NK
    Stelfox, HT
    Detsky, AS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (05): : 612 - 617
  • [9] Committee on quality of health care in America-Institute of Medicine, 2001, CROSS QUAL CHASM NEW
  • [10] Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop
    De Gruttola, VG
    Clax, P
    DeMets, DL
    Downing, GJ
    Ellenberg, SS
    Friedman, L
    Gail, MH
    Prentice, R
    Wittes, J
    Zeger, SL
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (05): : 485 - 502